Anti-TGF-β antibody blocks enamel matrix derivative-induced upregulation of p21WAF1/cip1 and prevents its inhibition of human oral epithelial cell proliferation

Journal of Periodontal Research

Volumn 37, Issue 4, 2002, Pages 255-262

  Kawase, Tomoyuki ^a   Okuda, Kazuhiro ^a   Yoshie, Hiromasa ^a   Burns, Douglas M ^b  

^a NIIGATA UNIVERSITY   (Japan)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Enamel matrix derivative; Intracellular signaling; TGF , proliferation, epithelial cells

Indexed keywords

ANTIBODY; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DNA; DNA BINDING PROTEIN; ENAMEL MATRIX PROTEINS; ENAMEL PROTEIN; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGENIC AGENT; SMAD2 PROTEIN; SMAD2 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; CELL CULTURE; CELL DIVISION; CELL NUCLEUS; COMPARATIVE STUDY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; EPITHELIUM CELL; FIBROBLAST; HUMAN; IMMUNOLOGY; MOUTH MUCOSA; PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; STATISTICS; UPREGULATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES; CELL DIVISION; CELL NUCLEUS; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DENTAL ENAMEL PROTEINS; DNA; DNA-BINDING PROTEINS; ENZYME INHIBITORS; EPITHELIAL CELLS; FIBROBLASTS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MITOGENS; MOUTH MUCOSA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN TRANSPORT; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; STATISTICS; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 0036690146     PISSN: 00223484     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0765.2002.01615.x     Document Type: Article

References (20)

1. Hammarström L, Heijl L, Gestrelius S. Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins. J Clin Periodontol 1997;24:669-677
2. Zetterstiom O. Andersson C. Eriksson L et al. Clinical safety of enamel matrix derivative (Emdogain®) in the treatment of periodontal defects J Clin Peritodontol 1997.24:697-704.
3. Heijl L, Heden G, Svārdström G, Ostgren A. Enamel matrix derivative (Emdogam®) in the treatment of intrabony periodontal defects. J Clin Perindontol 1997,24:705-714.
4. Rasperini G, Ricci G, Silvestri M. Surgical technique for treatment of infrabony defects with enamel matrix derivative (Emdogain®): 3 case reports. Int J Periodont Rest Dent 1999;19:578-587.
5. Sculean A, Reich E, Chiantella GC, Brecx M. Treatment of intrabony periodontal defects with an enamel matrix protein derivative (Emdogain®) a report of 32 cases Int J Pertodont Rest Dent 1999;19: 157-163
6. Sculean A, Donos N, Windisch P et al. Healing of human intiabony defects following treatment with enamel matrix proteins or guided tissue regeneration. J Periodont Res 1999;34:310-322.
7. Heden G. Wennstrom J, Lindhe J. Periodontal tissue alterations following Emdogain treatment of periodontal sites with angular bone defects. A series of case reports. J Clin Periodontol 1999;26:855-860.
8. Pontoriero R, Wennstrom J, Lindhe J. The use of barrier membranes and enamel matrix proteins in the treatment of angular bone defects. A prospective controlled clinical study. J Clin Periodonlol 1999;26: 833-840.
9. Sculean A, Donos N, Blaes A et al. Comparison of enamel matrix proteins and bioabsorbable membranes in the treatment of intrabony periodontal defects. A split-mouth study. J Periodontol 1999;70:255-262.
10. Yukna RA, Mellonig JT. Histologic evaluation of periodontal healing in humans following regenerative therapy with enamel matrix derivative. A 10-case series. J Periodontol 2000;71:752-759
11. Okuda K, Momose M, Miyazaki A et al. Enamel matrix derivative in the treatment of human intrabony periodontal osseous defects. J Periodontol 2000,71:1821-1828.
12. Okuda K, Miyazaki A, Momose M et al Levels of tissue inhibitor of metalloproteinases-1. matrix metalloproteinases-1 and -8 in gingival crevicular fluid following treatment with enamel matrix derivative (Emdogain®) J Periodont Res 2001; 36:309-316.
13. Slankin HC, Boyde A. Cementum: an epithelial secretory product? J Dent Res 1975;53:157.
14. Hammarström L. Enamel matrix, cementum development and regeneration. J Clin Periodontol 1997;24:658-668.
15. Gestrelius S, Andersson C, Johansson A-C et al. Formulation of enamel matrix derivative for surface coating. Kinetics and cell colonization. J Clin Periodontol 1997; 24:678-684.
16. Gestrelius S, Andersson C, Lidström D, Hammarström L, Somcrman M. in vitro studies on periodontal ligament cells and enamel matrix derivative. J Clin Periodonlol 1997;24:685-692.
17. Kawase T, Okuda K, Yoshie H, Burns DM Cytostatic action of enamel matrix derivative (Emdogain®) on human oral squamous cell carcinoma-derived SCC25 epithelial cells J Periodont Res 2000;35: 91-300
18. Kawase T, Okuda K, Momose M et al. Enamel matrix derivative (Emdogain®) rapidly stimulates phosphorylation of the MAP kinase family and nuclear accumulation of smad2 in both oral epithelial and fibroblastic human cells. J Periodont Res 2001;36:367-376
19. Kawase T, Okuda K, Wu C-H et al. Calcitonin gene-related peptide acts as a mitogen for human Gin-1 gingival fibroblasts by activating the MAP kinase signalling pathway. J Periodont Res 1999,34:160-168.
20. Miyamoto S, Akiyama SK, Yamada KM. Synergistic roles for receptor occupancy and aggregation in integrin transmembrane function Science 1995,267: 883-885.